|Awarded On||February 21, 2019|
|Title||Therapeutic Potential of T Follicular Helper Cells for Melanoma Treatment|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Roza Nurieva|
*Pending contract negotiation
Cancer is the number one cause of death worldwide and approximately 75% of skin cancer deaths are from melanoma. To date, adoptive T cell therapy is a promising approach to reactivate the patient’s own immune system to fight against tumors. While adoptive transfer of tumor-infiltrating lymphocytes enriched with cytotoxic CD8+ T cells (CTLs) have resulted in a 50% response rate in multiple phase II clinical trials in metastatic melanoma, CTL transfer alone does not improve clinical response suggesting an essential role of helper CD4+ T cells. There is increasing evidence on the potential function of a CD4+ T helper subset, named as T follicular helper (Tfh) cells in triggering anti-tumor acti...